Tivic Health Systems (Nasdaq:TIVC) - Aktienkurs, Nachrichten und Analyse

TIVC Aktienübersicht

Tivic Health Systems Inc. ist ein Health-Tech-Unternehmen, das sich auf die Entwicklung und Vermarktung von bioelektronischer Medizin konzentriert.

Über das Unternehmen

TIVC grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($2M)

Earnings have declined by 14.9% per year over past 5 years

Does not have meaningful revenue ($1M)

+ 1 mehr Risiko

Tivic Health Systems, Inc. Wettbewerber

Avinger

NasdaqCM:AVGR

US$1.8m

QHSLab

OTCPK:USAQ

US$1.8m

Helius Medical Technologies

NasdaqCM:HSDT

US$1.8m

Nuwellis

NasdaqCM:NUWE

US$2.5m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Tivic Health Systems
Historische Aktienkurse
Aktueller Aktienkurs	US$0.30
52-Wochen-Hoch	US$3.21
52-Wochen-Tief	US$0.22
Beta	2.48
11 Monat Veränderung	16.78%
3 Monate Veränderung	-29.04%
1 Jahr Veränderung	-74.79%
33 Jahre Veränderung	n/a
5 Jahre Veränderung	n/a
Veränderung seit IPO	-99.94%

Aktuelle Nachrichten und Updates

Recent updates

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Oct 17

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

Jul 15

Aktionärsrenditen

	TIVC	US Medical Equipment	US Markt
7D	1.7%	0.2%	-1.6%
1Y	-74.8%	25.8%	30.8%

Rendite im Vergleich zur Industrie: TIVC underperformed the US Medical Equipment industry which returned 25.8% over the past year.

Rendite vs. Markt: TIVC underperformed the US Market which returned 30.8% over the past year.

Preisvolatilität

Is TIVC's price volatile compared to industry and market?
TIVC volatility
TIVC Average Weekly Movement	13.3%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: TIVC's share price has been volatile over the past 3 months compared to the US market.

Volatilität im Zeitverlauf: TIVC's weekly volatility has decreased from 22% to 13% over the past year, but is still higher than 75% of US stocks.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2016	9	Jennifer Ernst	tivichealth.com

Tivic Health Systems Inc. ist ein Health-Tech-Unternehmen, das sich auf die Entwicklung und Vermarktung von bioelektronischer Medizin konzentriert. Sein Hauptprodukt ist ClearUP, ein bioelektronisches Medikament zur Behandlung von Nasennebenhöhlen- und Nasenentzündungen. Das Unternehmen vertreibt seine Produkte im Direktvertrieb über seine eigenen Websites und Plattformen wie Amazon.com und Walmart.com sowie an US-Online-Händler wie BestBuy und FSAStore und über Vertriebshändler.

Tivic Health Systems, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Tivic Health Systems im Vergleich zum Marktanteil des Unternehmens?
TIVC grundlegende Statistiken
Marktanteil	US$1.86m
Gewinn(TTM)	-US$6.75m
Umsatz(TTM)	US$1.11m

1.7x

Kurs-Umsatz-Verhältnis

-0.3x

Kurs-Gewinn-Verhältnis

Ist TIVC zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
TIVC Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$1.11m
Kosten der Einnahmen	US$803.00k
Bruttogewinn	US$310.00k
Sonstige Ausgaben	US$7.06m
Umsatz	-US$6.75m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.09
Bruttomarge	27.85%
Nettogewinnspanne	-606.47%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich TIVC auf lange Sicht entwickelt?

Historische Performance und Vergleiche

TIVC Aktienübersicht

Belohnungen

Risikoanalyse

Tivic Health Systems, Inc. Wettbewerber

NasdaqCM:AVGR

US$1.8m

OTCPK:USAQ

US$1.8m

NasdaqCM:HSDT

US$1.8m

NasdaqCM:NUWE

US$2.5m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Tivic Health Systems, Inc Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

Tivic Health® Systems, Inc. Announces Chief Financial Officer Changes

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering in the amount of $20.000001 million.

Second quarter 2024 earnings released: US$0.32 loss per share (vs US$7.16 loss in 2Q 2023)

Tivic Health Systems Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Tivic Health Systems, Inc., Annual General Meeting, Aug 09, 2024

Recent updates

Tivic Health Systems, Inc Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

Tivic Health® Systems, Inc. Announces Chief Financial Officer Changes

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering in the amount of $20.000001 million.

Second quarter 2024 earnings released: US$0.32 loss per share (vs US$7.16 loss in 2Q 2023)

Tivic Health Systems Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Tivic Health Systems, Inc., Annual General Meeting, Aug 09, 2024

Tivic Health Systems, Inc. Announces Board of Director Changes

First quarter 2024 earnings released: US$1.01 loss per share (vs US$10.52 loss in 1Q 2023)

Tivic Health Systems, Inc. to Report Q1, 2024 Results on May 15, 2024

Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (Vns); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$10.40 loss per share (vs US$104 loss in FY 2022)

Tivic Health Announces Completion of Enrollment for Study of Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Tivic Health Systems, Inc. Announces Termination of Ryan Sabia as Chief Operating Officer

Tivic Health Systems, Inc. Announces Launch of Second Generation of Tivic ClearUP

Third quarter 2023 earnings released: US$1.48 loss per share (vs US$26.70 loss in 3Q 2022)

Tivic Health Systems, Inc. Regains Compliance With Nasdaq Listing Requirements

Tivic Health Funded Study Begins Enrollment for Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Second quarter 2023 earnings released: US$0.072 loss per share (vs US$0.31 loss in 2Q 2022)

Tivic Health Systems, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Tivic Health Systems, Inc. ClearUP Expands Target Market Offering to Include Individuals Who Are Sleep Deprived, Medication Restricted, and Athletes

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2022)

Tivic Health Systems, Inc. to Report Q1, 2023 Results on May 15, 2023

Tivic Health Launches B2b Portal, Accelerates Healthcare Commercial Sales Expansion

Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.90 loss in 3Q 2021)

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Tivic Health Systems, Inc. (NasdaqCM:TIVC) entered into an Asset Purchase Agreement to acquire Substantially all of the assets, and certain specified liabilities, of Reliefband Technologies, LLC for $33.5 million.

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.49 loss in 2Q 2021)

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

First quarter 2022 earnings released: US$0.23 loss per share (vs US$0.55 loss in 1Q 2021)

Tivic Health Systems, Inc., Annual General Meeting, Jun 14, 2022

High number of new and inexperienced directors

Tivic Health Systems, Inc. to Report Q4, 2021 Results on Apr 19, 2022

Tivic Health Systems, Inc. Appoints Sanjay Ahuja, as Senior Vice President, Quality Assurance & Regulatory Affairs

Full year 2021 earnings released: US$2.43 loss per share (vs US$1.58 loss in FY 2020)

Tivic Health Systems, Inc. Collaborates With Leading Medical Research Hospital on First Controlled Trial to Extend Tivic’s Bioelectronic Platform

High number of new and inexperienced directors

No independent directors

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Tivic Health Systems, Inc.'s Grundlagenzusammenfassung

1.7x

-0.3x

Erträge &amp; Einnahmen

Erträge & Einnahmen